Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 1;12(8):e055672.
doi: 10.1136/bmjopen-2021-055672.

Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis

Yunchun Zhou #  1   2 , Wei Mu #  3 , Jihua Zhang  1   2 , Shi Wu Wen  4   5   6 , Smita Pakhale  7   5   8
Affiliations
Meta-Analysis

Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis

Yunchun Zhou et al. BMJ Open. .

Abstract

Objective: To accurately estimate the global prevalence of non-tuberculous mycobacteria (NTM) in adults with non-cystic fibrosis (non-CF) bronchiectasis and to determine the proportion of NTM species and subspecies in clinical patients from 2006 to 2021.

Design: Systematic review and meta-analysis using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Data sources: Medline, Embase, Cochrane Library and Web of Science were searched for articles published between 2006 and 2021.

Eligibility criteria for selecting studies: We included all the prospective or retrospective studies without language restrictions and all patients were adults (≥18 years of age) with non-CF bronchiectasis. The studies estimated the effect size of the prevalence of NTM with a sample size ≥40, and patients were registered in and after 2006.

Data extraction and synthesis: Two reviewers screened the titles, abstracts and full texts independently. Relevant information was extracted and curated into tables. Risk of bias was evaluated following the Cochrane Collaboration's tool. Meta-analysis was performed with software R Statistics V.3.6.3 using random effect model with 95% CI. I2 index and Q statistics were calculated to assess the heterogeneity, and mixed-effects meta-regression analyses were performed to identify the sources of heterogeneity. The proportions of NTM subspecies were examined using Shapiro-Wilk normality test in R.

Results: Of all the 2014 studies yielded, 24 met the inclusion criteria. Of these, 14 were identified to be randomised controlled studies and included for an accurate estimation. The global prevalence of NTM in adults with non-CF bronchiectasis from 2006 to 2021 was estimated to be approximately 10%, with great variations primarily due to geographical location. Mycobacterium avium complex was the most common subspecies, followed by Mycobacterium simiae and Mycobacterium gordonae.

Conclusions: The prevalence of NTM in adults with non-CF bronchiectasis has been on the rise and the most common subspecies changed greatly in recent years. More cohort studies should be done in many countries and regions for future estimates.

Prospero registration number: CRD42020168473.

Keywords: bacteriology; epidemiology; microbiology; respiratory infections.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Figure 2
Figure 2
Forest plot of all included 24 studies from the systematic review.
Figure 3
Figure 3
Forest plot of a sensitivity analysis of 14 studies for an accurate estimate of global prevalence of NTM in adults with non-CF bronchiectasis in 2006–2021. CF, cystic fibrosis; NTM, non-tuberculous mycobacteria.
Figure 4
Figure 4
Forest plot for subgroup analysis by geographical location.
See this image and copyright information in PMC

References

    1. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis 2017;14:377–84. 10.1177/1479972317709649 - DOI - PMC - PubMed
    1. Quint JK, Millett ERC, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016;47:186–93. 10.1183/13993003.01033-2015 - DOI - PMC - PubMed
    1. Martinez-Garcia MA, Polverino E, Aksamit T. Bronchiectasis and Chronic Airway Disease: It Is Not Just About Asthma and COPD. Chest 2018;154:737–9. 10.1016/j.chest.2018.02.024 - DOI - PubMed
    1. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108:955–61. 10.1378/chest.108.4.955 - DOI - PubMed
    1. Griffith DE, Aksamit TR. Bronchiectasis and nontuberculous mycobacterial disease. Clin Chest Med 2012;33:283–95. 10.1016/j.ccm.2012.02.002 - DOI - PubMed

LinkOut - more resources